Zhu Wenhao, Zhao Renshan, Guan Xiaomin, Wang Xu
Cancer Center, The First Hospital of Jilin University, Changchun, China.
Front Pharmacol. 2023 May 22;14:1192495. doi: 10.3389/fphar.2023.1192495. eCollection 2023.
Prostate cancer (PCa), bladder cancer (BC), and renal cell cancer (RCC) are the most common urologic tumours in males. N6-methyladenosine (mA), adenosine N6 methylation, is the most prevalent RNA modification in mammals. Increasing evidence suggests that mA plays a crucial role in cancer development. In this review, we comprehensively analyzed the influence of mA methylation on Prostate cancer, bladder cancer, and renal cell cancer and the relationship between the expression of relevant regulatory factors and their development and occurrence, which provides new insights and approaches for the early clinical diagnosis and targeted therapy of urologic malignancies.
前列腺癌（PCa）、膀胱癌（BC）和肾细胞癌（RCC）是男性中最常见的泌尿系统肿瘤。N6-甲基腺苷（m6A），即腺苷N6甲基化，是哺乳动物中最普遍的RNA修饰。越来越多的证据表明，m6A在癌症发展中起关键作用。在本综述中，我们全面分析了m6A甲基化对前列腺癌、膀胱癌和肾细胞癌的影响，以及相关调控因子的表达与其发生发展之间的关系，这为泌尿系统恶性肿瘤的早期临床诊断和靶向治疗提供了新的见解和方法。
Zotero 插件
